Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Blood (2021) 137 (20): 2817–2826.

https://doi.org/10.1182/blood.2020007376

Published: 2021

Includes: Supplemental data

Journal Articles

PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation

Martin K. Safo, PhD, Piyusha P Pagare, PhD, Mohini Ghatge, PhD, Carla Casu, PhD, Valentina Ghiaccio, PhD, Nancy Anabaraonye, Xiaomeng Xu, MS, Stefano Rivella, PhD, Patrick C. Hines, MD PhD, Ke Liu, PhD, Yan Zhang, PhD, Jürgen Venitz, MD PhD, Osheiza Abdulmalik, DVM

Blood (2019) 134 (Supplement_1): 73.

https://doi.org/10.1182/blood-2019-128646

Published: 2019

Journal Articles

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Neal J Weinreb, MD, Timothy M Cox, MD, Pramod K. Mistry, MD PhD FRCP, Joel Charrow, MD, Elena Lukina, MD PhD Professor, Meredith C. Foster, ScD, M. Judith Peterschmitt, MD

Blood (2019) 134 (Supplement_1): 4859.

https://doi.org/10.1182/blood-2019-127337

Published: 2019

Journal Articles

Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials

Pramod K. Mistry, MD PhD FRCP, Joel Charrow, MD, Timothy Cox, MD, Elena Lukina, MD PhD, Theodore Marinakis, MD, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD, Judith Peterschmitt, MD

Blood (2018) 132 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2018-99-117289

Published: 2018

Journal Articles

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

Marcio M Andrade-Campos, PhD, Jorge J Cebolla, MSc, Laura Lopez de Frutos, PhD, Pilar Irun, PhD, Soledad Noya, MD, Santiago Nieto, MD, Lucia Villalon, PhD, Ana I Arribas, MD, Abelardo Barez, PhD, Javier Garcia-Frade, PD, Maria Lourdes Hermosin, MD, Jesús-María Hernández-Rivas, MD PhD, Daiana Ibarretxe, MD, Maria L Lozano, MD PhD, Teresa Molero, PhD, Maria Angeles Perez-Saenz, MDPhD, Jesus Villarrubia, PhD, Pilar Giraldo, PhD

Blood (2018) 132 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2018-99-115534

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Long-Term Hematologic Response to Oral Eliglustat in Treatment-Naive Patients with Gaucher Disease Type 1: Final Results from a Phase 2 and the Phase 3 Engage Trials

Heather Lau, MD, Elena Lukina, MD, Pramod Mistry, MD, Yaoshi Wu, Sebastiaan J.M. Gaemers, MD, M. Judith Peterschmitt, MD

Blood (2017) 130 (Supplement 1): 448.

https://doi.org/10.1182/blood.V130.Suppl_1.448.448

Published: 2017

Journal Articles

Acetaminophen Caused Transfusion Dependent Children Repeated Hepatitis

Ching-Tien Peng, MD MPH, Chien-Yu Lin, Kang-Hsi Wu, Tefu Weng, Jan-Gowth Chang, Wan-Yu Lo

Blood (2017) 130 (Supplement 1): 4930.

https://doi.org/10.1182/blood.V130.Suppl_1.4930.4930

Published: 2017

Journal Articles

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Alexander V Lavrov, MD PhD, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Chelysheva, MD, Oleg Shukhov, MD, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Prof., MD, Sergey Kutsev

Blood (2016) 128 (22): 5457.

https://doi.org/10.1182/blood.V128.22.5457.5457

Published: 2016

Journal Articles

Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials

Neal J. Weinreb, MD FACP, Timothy M Cox, MD, Elena Lukina, MD, Pramod Mistry, MD PhD FRCP, Jennifer Angell, Sebastiaan Gaemers, MD, M. Judith Peterschmitt, MD

Blood (2015) 126 (23): 884.

https://doi.org/10.1182/blood.V126.23.884.884

Published: 2015

Journal Articles

Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors

Ahmet H Elmaagacli, MD, PhD, Michael Koldehoff, MD, Nina Kristin Steckel, Markus Ditschkowski, Rudolf Trenschel, MD, Hellmut Ottinger, Dietrich W. Beelen, MD

Blood (2012) 120 (21): 4182.

https://doi.org/10.1182/blood.V120.21.4182.4182

Published: 2012

Journal Articles

Results of Simultaneously Performed Analysis of 48 Gene Variants Reported to Have Influence on Transplant outcome

Ahmet Elmaagacli, MD, Michael Koldehoff, MD, Nina Steckel, Hellmut Ottinger, Dietrich Beelen

Blood (2011) 118 (21): 3047.

https://doi.org/10.1182/blood.V118.21.3047.3047

Published: 2011

Journal Articles

Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML

Blood (2010) 116 (21): 2272.

https://doi.org/10.1182/blood.V116.21.2272.2272

Published: 2010

Journal Articles

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Dong-Wook Kim, MD, PhD, Sa-Hee Park, Yu Jin, MS, Michael Hayes, PhD, Yanfeng Wang, PhD

Blood (2008) 112 (11): 5056.

https://doi.org/10.1182/blood.V112.11.5056.5056

Published: 2008

Journal Articles

Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients.

Simona Soverini, Sabrina Angelini, Eleonora Turrini, Alessandra Gnani, Sabrina Colarossi, Giovanni Perini, Ilaria Iacobucci, Patrizia Hrelia, Giorgio Cantelli Forti, Daniela Cilloni, Giuseppe Saglio, Fabrizio Pane, Michele Baccarani, Thea Kalebic, Giovanni Martinelli

Blood (2007) 110 (11): 1946.

https://doi.org/10.1182/blood.V110.11.1946.1946

Published: 2007

Journal Articles

Effect of Deferasirox on Midazolam Pharmacokinetics.

Caroline Arrowsmith-Bensasson, Lisa Rojkjaer, Venkat Sethuraman, Andrej Skerjanec

Blood (2007) 110 (11): 3826.

https://doi.org/10.1182/blood.V110.11.3826.3826

Published: 2007

Journal Articles

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Charles Dumontet, MD, PhD, Stefano Landi, PhD, Tony Reiman, MD, PhD, Adriana Plesa, MD, Ilaria Bellini, PhD, Roberto Barale, PhD, Linda M. Pilarski, MD, Sean Tavtigian, PhD, Troy Perry, BsC, Federica Gemignani, PhD

Blood (2007) 110 (11): 4746.

https://doi.org/10.1182/blood.V110.11.4746.4746

Published: 2007

Journal Articles

Sickle Cell Pain Crisis: The Effect of CYP2D6 Polymorphisms.

David C. Brousseau, MD, MS, D. Gail McCarver, MD, Julie A. Panepinto, MD, MSPH

Blood (2005) 106 (11): 2318.

https://doi.org/10.1182/blood.V106.11.2318.2318

Published: 2005

Journal Articles

A New Genotyping Chip for Childhood ALL: Using a Novel Multiplex Allele-Specific Primer Extension Strategy To Detect Twelve Polymorphisms in Six Genes Encoding for Drug-Metabolizing Enzymes.

Yi Lu, Kow-Yin Kham, Eng-Juh Yeoh

Blood (2004) 104 (11): 4500.

https://doi.org/10.1182/blood.V104.11.4500.4500

Published: 2004

Journal Articles

Susceptibility to Childhood Acute Lymphoblastic Leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 Genetic Polymorphisms

Maja Krajinovic, Damian Labuda, Chantal Richer, Sepideh Karimi, Daniel Sinnett

Blood (1999) 93 (5): 1496–1501.

https://doi.org/10.1182/blood.V93.5.1496

Published: 1999

NARROW

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials

Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Long-Term Hematologic Response to Oral Eliglustat in Treatment-Naive Patients with Gaucher Disease Type 1: Final Results from a Phase 2 and the Phase 3 Engage Trials

Acetaminophen Caused Transfusion Dependent Children Repeated Hepatitis

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials

Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors

Results of Simultaneously Performed Analysis of 48 Gene Variants Reported to Have Influence on Transplant outcome

Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients.

Effect of Deferasirox on Midazolam Pharmacokinetics.

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Sickle Cell Pain Crisis: The Effect of CYP2D6 Polymorphisms.

A New Genotyping Chip for Childhood ALL: Using a Novel Multiplex Allele-Specific Primer Extension Strategy To Detect Twelve Polymorphisms in Six Genes Encoding for Drug-Metabolizing Enzymes.

Susceptibility to Childhood Acute Lymphoblastic Leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 Genetic Polymorphisms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only